| Excerpt | Reference |
|---|
| "Lymphatic filariasis is manifested by a spectrum of symptoms that range from microfilaraemia to gross immunopathology." | ( Bundy, DA; Grenfell, BT; Rajagopalan, PK, 1991) |
| "Lymphatic filariasis is the most widespread of human filarial infections, a group of vector-borne infestations." | ( Navaratnam, V, 1993) |
| "Lymphatic filariasis is a disease of the poor and underprivileged and has received little attention in the past." | ( Bandyopadhyay, L, 1996) |
| "Lymphatic filariasis is caused by a nematodal infection with Wuchereria or Brugia species." | ( Cunningham, NM, 1997) |
| "Lymphatic filariasis is a major public health problem, affecting 120 million people in 73 countries." | ( Lakshmi, A, 2000) |
| "Lymphatic filariasis is a widespread infectious disease of children in endemic areas, but little is known about the early lymphatic damage in children and its evolution, either with or without treatment." | ( Amaral, F; Carvalho, K; Dreyer, G; Figueredo-Silva, J; Ottesen, EA, 2001) |
| "Lymphatic filariasis is associated with considerable disability related to the intensity and frequency of acute adenolymphangitis (ADL) attacks." | ( Kumaraswami, V; Shenoy, RK; Suma, TK, 2002) |
| "Lymphatic filariasis is a considerable public health problem on this island with an overall endemicity rate of 16." | ( Murhekar, MV; Ramaiah, KD; Sehgal, SC; Shriram, AN, 2002) |
| "Lymphatic filariasis is a major health problem in many parts of the tropical world." | ( Kumaraswami, V; Shenoy, RK; Suma, TK, 2003) |
| "In countries where bancroftian filariasis is endemic, lymphedema of the leg is a public health problem, particularly for women, who are disproportionately affected." | ( Addiss, DG; Guarner, J; Jones, TL; Louis-Charles, J; Valme, AL; Wilson, SF, 2004) |
| "Patent lymphatic filariasis is characterized by a profound down-regulation of immune responses with both parasite Ag-specific tolerance and bystander suppression." | ( Babu, S; Blauvelt, CP; Kumaraswami, V; Nutman, TB, 2006) |
| "Lymphatic filariasis is targeted to be eliminated globally, at least as a public-health problem, by 2020." | ( Bradley, MH; Gunawardena, GS; Ismail, MM; Karunaweera, ND, 2007) |
| "(1) Lymphatic filariasis is a set of parasitic diseases that are endemic in tropical and subtropical regions and can be disabling in the long term." | ( , 2008) |
| "If lymphatic filariasis is to be eliminated from India in a reasonable time-frame, at least as a public-health problem, MDA should now be focused on the poorer localities." | ( Ramaiah, KD; Vijay Kumar, KN, 2008) |
| "Lymphatic filariasis is increasingly viewed as the result of an infection that is often acquired in childhood." | ( Dhananjayan, G; Kumaraswami, V; Padma, S; Rahmah, N; Shenoy, RK; Suma, TK, 2009) |
| "Lymphatic filariasis is a major health problem in India with a large number of patients tending to be asymptomatic." | ( Daga, MK; Garg, Sk; Kumar, R; Mohanty, PK; Nayak, HK; Pandey, BK; Sinha, Nk, 2011) |
| "Lymphatic filariasis is one of the major public health problems across the globe." | ( Aggarwal, A; Dev, M; Misra, K; Rajashekaraiah, LC; Sharma, V, 2011) |
| "Lymphatic filariasis is a vector borne parasitic disease causing long term disability." | ( Das, LK; J, Y; Kumari, AK, 2012) |
| "Lymphatic filariasis is a debilitating disease caused by clade III parasites like Brugia malayi and Wuchereria bancrofti." | ( Buxton, SK; Martin, RJ; Robertson, AP, 2013) |
| "Lymphatic filariasis is a major vector-borne disease and India bears 81% of the filariasis burden in South East Asia." | ( Barde, PV; Chand, G; Singh, N, 2013) |
| "Lymphatic filariasis is a common parasitic disease of cats in tropical regions including Thailand." | ( Chungpivat, S; Taweethavonsawat, P, 2013) |
| "Lymphatic filariasis is a neglected tropical disease leading to profound disfiguring causing socio economic burden in the tropics." | ( Ansel Vishal, L; Kaliraj, P; Mahalakshmi, N; Nazeer, Y; Ravishankaran, R, 2014) |
| "Lymphatic filariasis is an immune-mediated spectral disease that manifests as two main clinical outcomes: chronic pathology or asymptomatic infection." | ( Blanchard, V; Hartmann, S; O'Regan, NL; Rao, GB; Schwedler, C; Srikantam, A; Steinfelder, S, 2014) |
| "Lymphatic filariasis is still endemic in many parts of India." | ( Kumar, A; Sachan, P, 2014) |
| "Lymphatic filariasis is known to be associated with diminished CD4⁺ Th1 and elevated CD4⁺ Th2 responses to parasite-specific antigens." | ( Anuradha, R; Babu, S; George, PJ; Kumaran, P; Nutman, TB, 2014) |
| "Lymphatic filariasis is a debilitating disease caused by lymph dwelling nematodal parasites like Wuchereria bancrofti, Brugia malayi and Brugia timori." | ( Doharey, PK; Rathaur, S; Saxena, JK; Singh, SK; Verma, A; Verma, P, 2016) |
| "Lymphatic filariasis is targeted for elimination as a public health problem by 2020." | ( Hollingsworth, TD; Irvine, MA; Michael, E; Singh, BK; Smith, ME; Stolk, WA; Subramanian, S; Weil, GJ, 2017) |
| "Lymphatic filariasis is one of the most debilitating and disfiguring scourges among all diseases." | ( Mohapatra, DP; Mohapatra, MM; Panda, DK, 2017) |
| "Lymphatic filariasis is a tropical parasitic disease and is endemic in India." | ( Anantha, S; Chaudhary, A; Shukla, AD; Verma, AK, 2017) |
| "Lymphatic filariasis is a complex parasitic disease having a spectrum of clinical parameters which are critical in deciding the severity of the pathogenesis." | ( Panda, SK; Pati, S; Sahoo, PK; Satapathy, AK, 2018) |
| "Lymphatic filariasis is widely endemic in Myanmar." | ( Aye, NN; Bradbury, RS; Dickson, BFR; Douglass, J; Graves, PM; McBride, WJ; Nwe, TW; Shwe, M; Wai, T; Win, SS, 2018) |
| "Lymphatic filariasis is endemic in nine of the eleven Member States of the World Health Organization South East Asia Region." | ( Boondej, P; Gopinath, D; Khuanyoung, N; Prempree, P; Ramaiah, KD; Rojanapanus, S; Santabutr, W; Thammapalo, S; Toothong, T, 2019) |
| "Lymphatic filariasis is endemic in the Pacific Islands and was historically reported as elephantiasis in Micronesia." | ( Gahlinger, PM, 2021) |
| "Lymphatic filariasis is a serious public health issue." | ( Abd-Elsalam, S; Abdelazeem, B; Abuelazm, MT; Ashraf, M; Badr, H; Gamal, M, 2022) |
| "Lymphatic filariasis is a mosquito transmitted parasitic infection in tropical regions." | ( Chachage, M; Chiwerengo, N; Clowes, P; Debrah, A; Geldmacher, C; Haule, A; Hoelscher, M; Hoerauf, A; Horn, S; Kalinga, A; Kavishe, G; Kroidl, I; Lazarus, W; Maganga, L; Marandu, TF; Mhidze, J; Mnkai, J; Mosoba, M; Ngenya, A; Ntapara, E; Rieß, F; Saathoff, E; Urio, A, 2022) |
| "Lymphatic filariasis is a parasitic disease caused by nematodes affecting millions of individuals in the tropical region." | ( Balasubramaniyan, M; Perumal, K; Santhanam, M; Vinayagam, V, 2022) |
| "Lymphatic filariasis is a debilitating illness with an estimated 50 million cases as of 2018." | ( Eck, T; Frey, KM; Goodey, NM; Gubler, U; Janson, CA; Lange, K, 2023) |
| Excerpt | Reference |
|---|
| "One hundred thirty-two residents of a bancroftian filariasis-endemic area of Papua New Guinea (PNG) were treated with a 72 mg/kg dose of DEC." | ( Alpers, MP; Day, KP; Garner, P; Kazura, JW; Mitchell, GF; Raiko, A; Spark, R; Weiss, N; Wenger, JD, 1991) |
| "All patients with bancroftian filariasis became amicrofilaremic within one week after DEC treatment." | ( Cheng, WF; Fang, RL; Piessens, WF; Tao, ZH; Xu, M; Zheng, HJ, 1990) |
| "A pilot study for control of bancroftian filariasis through detection and treatment of microfilaria (mf) carriers and filaria disease cases with Diethylcarbamazine (DEC) undertaken in the rural areas of Srikakulam and Vizianagaram of Andhra Pradesh showed that this chemotherapeutic method of control of filaria in rural areas is feasible and acceptable to society." | ( Biswas, H; Das, M; Narasimham, MV; Rao, VG; Sharma, SP; Yadava, RL, 1989) |
| "Two patients, one with Bancroftian filariasis and the other with onchocerciasis, and two healthy controls were treated with diethylcarbamazine (DEC)." | ( Bygbjerg, IC; Pedersen, BK; Svenson, M, 1987) |
| "In 37 bancroftian filariasis carriers, 6 and 12 months after IVER 400 treatment, the microfilaremia recurrences were 3." | ( Cartel, JL; Chanteau, S; Glaziou, P; Martin, PM; Moulia-Pelat, JP; Nguyen, LN, 1993) |
| "The elimination of lymphatic filariasis as a public-health problem is currently dependent on the delivery of annual drug treatments to at least 80% of the eligible members of endemic populations for at least 5 years." | ( Gyapong, JO; Gyapong, M; Owusu-Banahene, G, 2001) |
| "The global initiative to eradicate bancroftian filariasis currently relies on mass treatment with four to six annual doses of antifilarial drugs." | ( Alexander, ND; Alpers, MP; Bockarie, F; Bockarie, MJ; Dimber, Z; Ibam, E; Kastens, W; Kazura, JW; Tisch, DJ, 2002) |
| "Ghanaian individuals ( n=93) with lymphatic filariasis and a minimum microfilaremia of 40 microfilariae/ml were included in a treatment study consisting of four arms: (1) doxycycline 200 mg/day for 6 weeks; (2) doxycycline as in (1), followed by a single dose of ivermectin after 4 months; (3) ivermectin only; or (4) no treatment during observation period of 1 year (ivermectin at the end of the study)." | ( Adjei, O; Büttner, DW; Debrah, AY; Fischer, K; Hoerauf, A; Kruppa, T; Mand, S; Marfo-Debrekyei, Y; Pfarr, KM, 2003) |
| "Severe adverse reactions to lymphatic filariasis treatment using DEC with or without albendazole are uncommon." | ( Addiss, DG; Beach, MJ; Lafontant, J; Lammie, J; Lammie, PJ; McLaughlin, SI; Michel, MC; Radday, J; Rheingans, R, 2003) |
| "The Global Program for Elimination of Lymphatic Filariasis calls for mass drug administration for endemic populations outside of sub-Saharan Africa with a single dose of diethylcarbamazine (DEC) and albendazole (Alb) annually for 4-6 years." | ( Ahmed, ES; El Setouhy, M; Farid, HA; Helmy, H; Hussain, O; Kandil, AM; Ramzy, RM; Weil, GJ, 2004) |
| "A two-arm community-based lymphatic filariasis elimination trial is being carried out in Tamil Nadu state, India to assess the effect of 2 annual single-dose mass drug administrations of diethylcarbamazine + albendazole (DEC + ALB) on microfilaraemia and antigenaemia in one arm, and diethylcarbamazine(DEC) alone in the other arm." | ( Abdullah, SM; Arunachalam, N; Mani, TR; Munirathinam, A; Rajendran, R; Satyanarayana, K; Sunish, IP, 2004) |
| "Current programmes to eliminate lymphatic filariasis (LF) are largely based on annual mass administrations of single doses of antifilarial drugs." | ( Das, PK; Pani, SP; Ramaiah, KD; Subramanian, S; Vanamail, P; Yuvaraj, J, 2005) |
| "In India, the programme to eliminate lymphatic filariasis, which is largely based on mass administrations of diethylcarbamazine, has, in terms of coverage and compliance, been generally much less successful in urban areas than in rural communities." | ( Babu, BV; Behera, DK; Kar, SK; Kerketta, AS; Mishra, S; Rath, K; Swain, BK, 2006) |
| "Global efforts to control lymphatic filariasis by annual mass treatment with DEC may have a beneficial effect on the HIV/AIDS epidemic in areas where HIV and lymphatic filariasis co-exist." | ( Dalgaard, P; Friis, H; Krarup, H; Magesa, S; Magnussen, P; Nielsen, NO; Simonsen, PE, 2007) |
| "Because lymphatic filariasis (LF) elimination efforts are hampered by a dearth of economic information about the cost of mass drug administration (MDA) programs (using either albendazole with diethylcarbamazine [DEC] or albendazole with ivermectin), a multicenter study was undertaken to determine the costs of MDA programs to interrupt transmission of infection with LF." | ( Aikins, M; Amarillo, ML; Belizario, VY; Brady, MA; Garshong, B; Goldman, AS; Guisinger, VH; Gyapong, J; Haddix, AC; Kabali, C; Kamal, HA; Kanjilal, S; Kyelem, D; Lizardo, J; Malecela, M; Mubyazi, G; Nitièma, PA; Ottesen, EA; Ramzy, RM; Rheingans, R; Streit, TG; Wallace, A, 2007) |
| "The global program to eliminate lymphatic filariasis (LF) is currently based on mass drug administration (MDA) with annual single dose of antifilarials." | ( Babu, BV; Kerketta, AS, 2009) |
| "Standard treatment of lymphatic filariasis with diethylcarbamazine (DEC) is associated with systemic adverse reactions, thought to be due to the release of microfilariae material and Wolbachia endosymbiotic bacteria into the blood." | ( Nuchprayoon, S; Sanprasert, V; Sujariyakul, A, 2010) |
| "Croix to implement MDA for treatment of lymphatic filariasis and soil-transmitted helminthiasis by using once a year treatment with albendazole and diethylcarbamazine in a population of approximately 8 million persons." | ( Baker, M; Brady, MA; Desir, L; Direny, A; Goldman, AS; Linehan, M; Oscard, R; Vely, JF, 2011) |
| "The Global Programme to Eliminate Lymphatic Filariasis aims to achieve its objective through two strategies; Mass Drug Administration (MDA) to interrupt transmission and Morbidity Management (MM) to manage disability for those already affected." | ( Das, LK; J, Y; Kumari, AK, 2012) |
| "The Global Programme to Eliminate Lymphatic Filariasis was launched with the goal of eliminating this disease via the annual mass drug administration (MDA) of a single dose of antifilarial drugs." | ( Braga, C; Costa, GM; Lima, AW; Medeiros, Z; Santos, ZC, 2012) |
| "Currently lymphatic filariasis (albendazole/ivermectin) and trachoma (azithromycin) are treated separately." | ( Coulibaly, YI; Daou, A; Dicko, I; Doumbia, M; Haidara, FC; Horton, J; Keita, M; Keita, MM; Sankare, MH; Sow, SO; Whately-Smith, C, 2013) |
| "Our current strategy against lymphatic filariasis which combines annual mass drug administration, systematic treatment of antigenemic and microfilaraemic patients, and vector control; failed to reach the target of 1% prevalence." | ( Musso, D, 2013) |
| "Control of lymphatic filariasis (LF) in most countries of sub-Saharan Africa is based on annual mass drug administration (MDA) with a combination of ivermectin and albendazole, in order to interrupt transmission." | ( Derua, YA; Kisinza, WN; Magesa, SM; Malecela, MN; Pedersen, EM; Simonsen, PE, 2013) |
| "Global efforts to eliminate lymphatic filariasis are based on the annual mass administration of antifilarial drugs to reduce the microfilaria reservoir available to the mosquito vector." | ( Baea, ME; Bockarie, MJ; Dagoro, H; Henry-Halldin, CN; Hetzel, MW; Kazura, JW; Michael, E; Reimer, LJ; Siba, PM; Susapu, M; Thomsen, EK; Tisch, DJ; Zimmerman, PA, 2013) |
| "Under the Global Programme to Eliminate Lymphatic Filariasis (LF), mass drug administration (MDA) is being implemented in Tamil Nadu, south India, by the State health machinery." | ( Ashok Kumar, V; Kalimuthu, M; Munirathinam, A; Sunish, IP; Tyagi, BK, 2014) |
| "Mass drug administration (MDA) for lymphatic filariasis (LF) programs has delivered more than 2 billion treatments of albendazole, in combination with either ivermectin or diethylcarbamazine, to communities co-endemic for soil-transmitted helminthiasis (STH), reducing the prevalence of both diseases." | ( 'Ake, M; Addiss, DG; Adjinacou, E; Batcho, W; Chu, BK; Dorkenoo, AM; Gass, K; Mafi, ', 2014) |
| "Efforts to eliminate onchocerciasis and lymphatic filariasis in Central Africa through mass drug administration have been suspended because of ivermectin-associated serious adverse events, including death, in patients infected with the filarial parasite Loa loa." | ( Bakalar, M; Bennuru, S; Boussinesq, M; D'Ambrosio, MV; Fletcher, DA; Kamgno, J; Nilsson, L; Nutman, TB; Pion, S; Reber, C; Skandarajah, A; Switz, N, 2015) |
| "Available treatments for lymphatic filariasis (LF) are limited in their longterm clearance of microfilaria from the blood." | ( Baea, M; Fleckenstein, LL; Kazura, JW; King, CL; Lombore, B; Maki, E; Sanuku, N; Satofan, S; Schmidt, MS; Siba, PM; Thomsen, EK; Weil, GJ, 2016) |
| "A moderate but significant reduction in lymphatic filariasis prevalence and worm burden was demonstrated after two rounds of treatment with albendazole and ivermectin." | ( Clowes, P; Haule, A; Hoelscher, M; Hoerauf, A; Kowuor, D; Kroidl, I; Löscher, T; Maboko, L; Mabuye, J; Maganga, L; Makunde, WH; Malecela, MN; Mgeni, N; Mviombo, P; Mwingira, U; Pitter, B; Saathof, E, 2016) |
| "As the Global Programme to Eliminate Lymphatic Filariasis (LF) approaches its 2020 goal, an increasing number of districts will enter the endgame phase where drug coverage rates from mass drug administration (MDA) are used to assess whether MDA can be stopped." | ( Bradley, M; Damayanti, R; Krentel, A; Lynam, T; Suharno, N; Titaley, CR, 2016) |
| "Our aim was to assess the lymphatic filariasis situation, following mass drug administration." | ( Chandrasena, NT; de Silva, NR; Premaratna, R; Samarasekera, DS, 2016) |
| "The Tanzanian National Lymphatic Filariasis Elimination Programme reported annual treatment coverage for Rufiji District ranging from 54." | ( Derua, YA; Jones, C; Malecela, MN; Ngasalla, B; Tarimo, D, 2017) |
| "The Global Programme to Eliminate Lymphatic Filariasis (LF) aims to eliminate the disease as a public health problem by 2020 by conducting mass drug administration (MDA) and controlling morbidity." | ( Andreosso, A; Fuimaono, S; Graves, PM; Lau, CL; Roineau, M; Ryan, S; Sheridan, S; Tufa, J, 2017) |
| "Current WHO recommendations for lymphatic filariasis (LF) surveillance advise programs to implement activities to monitor for new foci of transmission after stopping mass drug administration (MDA)." | ( Fuimaono, S; Gass, K; Hamlin, KL; Kubofcik, J; Lammie, PJ; Nutman, TB; Robinson, K; Seespesara, M; Tufa, J; Wiegand, RE; Won, KY, 2018) |
| "WHO's Global Programme to Eliminate Lymphatic Filariasis (LF) uses mass drug administration (MDA) of anthelmintic medications to interrupt LF transmission in endemic areas." | ( Andersen, BJ; Budge, PJ; Herbert, C; Weil, GJ, 2018) |
| "The Global Program to Eliminate Lymphatic Filariasis has achieved extraordinary success in reducing transmission and preventing morbidity through mass drug administration (MDA) to the population at-risk." | ( Araújo, J; Braga, C; Brandão, E; da Silva, JSF; de Souza Melo, PFA; Duarte, FM; Feitosa Luna, C; Grilis, MR; Marcondes, M; Oliveira, P; Rocha, A, 2018) |
| "Control of lymphatic filariasis (LF) in most of the sub-Saharan African countries is based on annual mass drug administration (MDA) using a combination of ivermectin and albendazole." | ( Bockarie, M; Derua, YA; Jones, C; Malecela, MN; Ngasala, B; Reimer, L; Tarimo, D, 2018) |
| "The Global Program to Eliminate Lymphatic Filariasis (LF) relies on rapid diagnostic tests (RDTs) to determine where annual mass drug administration for LF is required and when it can be stopped." | ( Budge, PJ; Chawa Chunda, V; Fischer, PU; Hertz, MI; Jelil Njouendou, A; Kamgno, J; Nana-Djeunga, H; Rush, A; Wanji, S; Weil, GJ, 2018) |
| "The Global Programme to Eliminate Lymphatic Filariasis recommends mass treatment of albendazole co-administered with the microfilaricidal (antifilarial) drugs diethylcarbamazine (DEC) or ivermectin; and recommends albendazole alone in areas where loiasis is endemic." | ( Budhathoki, SS; Garner, P; Johnson, S; Macfarlane, CL; Richardson, M, 2019) |
| "Conventional oral therapy of lymphatic filariasis drugs is only effective to kill microfilariae in the bloodstream, but is often ineffective to kill adult filarial (macrofilariae) in the complex anatomy of the lymphatic system." | ( Anjani, QK; Donnelly, RF; McCarthy, HO; McCrudden, MTC; Permana, AD; Ramadon, D; Tekko, IA, 2019) |
| "Two coverage rates for MDA for lymphatic filariasis were subsequently calculated using the reported number treated divided by the total population from: 1) the pre-MDA register and 2) national census projections." | ( Baker, M; Bisanzio, D; Chowdhury, D; Conteh, A; Hodges, MH; Kamara, W; Koroma, JB; Macarthy, F; Magbity, E; Samai, M; Sonnie, M; Toubali, EH; Zoerhoff, KL, 2019) |
| "As new lymphatic filariasis infections are eliminated through mass chemotherapy, previously affected individuals are left with the sequellae, especially chronic progressive lymphoedema." | ( Budge, PJ; Coulibaly, Y; Deathe, D; Debrah, A; Debrah, LB; Hoerauf, A; Horton, J; Klarmann-Schulz, U; Krishnasastry, S; Kroidl, I; Mackenzie, C; Majewski, A; Mwingira, U; Ngenya, A; Nutman, TB; Ottesen, E; Shott, JP; Stephens, M; Sullivan, S; Wanji, S; Weerasooriya, M; Weil, G; Yahathugoda, C, 2020) |
| "The control of lymphatic filariasis (LF) caused by Wuchereria bancrofti in the Central African Region has been hampered by the presence of Loa loa due to severe adverse events that arise in the treatment with ivermectin." | ( Abong, RA; Akame, J; Amambo, G; Beng, AA; Biholong, B; Deribe, K; Enyong, PI; Esum, ME; Fombad, FF; Fru, J; Gandjui, NTV; Mbia, P; Nchanji, GT; Ndongmo, PWC; Njouendou, AJ; Nko'Ayissi, G; Reid, SD; Tougoue, JJ; Wanji, S; Zhang, Y, 2020) |
| "Achieving elimination of lymphatic filariasis (LF) as a public health problem requires a minimum of five effective rounds of mass drug administration (MDA) and demonstrating low prevalence in subsequent assessments." | ( Bah, Y; Baker, M; Batcho, W; Benjamin Didier, B; Bougma, R; Bougouma, C; Brady, M; Burgert-Brucker, CR; Coulibaly, YI; Doumbia, SS; Georges, N; Headland, M; Karim, MJ; Kraemer, J; Lemoine, JF; Marfo, B; Muheki, E; Mwingira, U; Ndayishimye, E; Nshala, A; Pangaribuan, HU; Rimal, P; Salissou, AB; Shoemaker, EA; Shott, J; Stelmach, R; Wijayanti, E; Yevstigneyeva, V; Zoerhoff, KL, 2020) |
| "The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission." | ( Jacobson, JA; King, JD; Weil, GJ, 2020) |
| "Improved treatments for lymphatic filariasis (LF) could accelerate the global elimination program for this disease." | ( Alfian, R; Bogus, J; Christian, M; Destani, Y; Djuardi, Y; Fischer, PU; Iskandar, E; Lew, D; Lomiga, A; Maylasari, R; Minggu, D; Supali, T; Weil, GJ, 2021) |
| "The efficacy of MOX for the treatment of lymphatic filariasis (LF) and its potential use in mass drug administration protocols for the elimination of LF is currently under evaluation." | ( Alshehri, A; Bala, V; Bjerum, C; Budge, PJ; Chhonker, YS; Fischer, PU; Gabo, TP; King, CL; Koudou, BG; Meïté, A; Murry, DJ; Ouattara, AF; Weil, GJ, 2023) |
| "India has targeted elimination of lymphatic filariasis (LF) through mass drug administration (MDA) by 2027." | ( Bal, M; Das, A; Dixit, S; Jain, HK; Krishnamoorthy, K; Mohanty, S; Panda, BB; Pati, S; Rahi, M; Ranjit, M; Somalkar, N, 2023) |